Wednesday, May 22, 2019

Amgen Seeks To Acquire Nuevolution For $167M

Thousand Oaks-based biotech giant Amgen has made a $167M offer for Danish company Nuevolution, saying early this morning that it made a cash offer of SEK 32.50 per share for publicly listed Nuevolution, a developer of small molecule drugs. Nuevolution is based in Copenhagen, Denmark, and develops small molecule drugs focused on treatment of targets

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.